KIT and gastrointestinal stromal tumor: A preclinical study in imatinib-resistant GIST using alternating regorafenib and sunitinib reported that regorafenib mainly inhibits KIT kinases with a mutation in the activation loop and sunitinib inhibits kinases with an ATP binding pocket mutation [21].